Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
A method and system of reducing the likelihood of a Porphyrmonas gingivalis infection in a human being includes the use of an anti-biofilm agent, compounds that facilitate the growth of desired bacteria beneficial to a person's health, and compositions that reduce the growth of Porphyrmonas gingivalis bacteria, thereby reducing the virulence factor gingipain. In other embodiments, the likelihood that a subject will suffer from neurodegenerative diseases, such as Alzheimer's Disease, is reduced by administering, via local gingival application to a subject that has been diagnosed with periodontitis, an effective amount of a composition to reduce Porphyrmonas gingivalis bacteria residing on the subgingival tooth area of the subject. Methods involve the targeting of the microbiome of an individual to promote health and to treat inflammatory diseases, including specifically neurodegenerative diseases, by the modification of an individual's oral microbiome and effective management of oral health care.
1. A method of reducing the likelihood of a Porphyromonas gingivalis infection in a human being comprising,
providing to a human being who has been diagnosed with periodontitis, a therapeutically effective amount of a first composition comprising an anti-biofilm agent,
administering to the human being a second composition that is effective to either slow down the breakdown of collagen or inhibit the production of collagenase; and
orally administering to the subgingival tooth area of the human being a third composition comprising an antibiotic in an effective amount to kill Porphyromonas gingivalis bacteria residing on the subgingival tooth area of the human being, wherein the method reduces the likelihood of a Porphyromonas gingivalis infection in the human being and reduces the virulence factor gingipain.
2. The method as set forth in claim 1 , further comprising administering to the human being a compound that facilitates the growth of desired bacteria beneficial to a person's health, said desired bacteria comprising one of a bacterium of the genus Rothia , a bacterium of species Lactobacillus salivarius and a bacterium of the species Streptococcus salivarius.
3. The method of claim 1 , wherein said second composition is devoid of manganese.
4. The method of claim 1 , wherein said second composition comprises an effective amount of paquinimod to inhibit collagenase activity.
5. The method as set forth in claim 1 , wherein said second composition includes between 0.2 and 0.9% xylitol by weight.
6. The method as set forth in claim 1 , wherein said antibiotic comprises one of azithromycin, metronidazole and ceftriaxone.
7. The method as set forth in claim 1 , further comprising administering to the human being Porphyromonas gingivalis that has been modified by using a clustered regularly interspaced short palindromic repeat (CRISPR) CRISPR associated protein (Cas) system, or a CRISPR/Cpf1 system, to reduce the virulence factor gingipain.
8. The method as set forth in claim 1 , wherein administration of the second composition is provided in the form of one of a toothpaste, a mouthwash, a chewing gum, a thin film strip, a lozenge, a dental floss, a food product, a gel, and a slow-release gel.
9. The method as set forth in claim 1 , wherein the second composition produces nitric oxide.
10. The method as set forth in claim 1 , wherein the second composition includes zinc or zinc salts.
11. The method as set forth in claim 1 , further comprising reducing the amount of F. nucleatum in the human being's oral cavity.
12. The method as set forth in claim 1 , further comprising providing the oral cavity of the human being with bacteria that have had one or more virulence factors eliminated to reduce adherence abilities of such bacteria in forming biofilms.
13. The method as set forth in claim 1 , the antibiotic is provided in an effective amount to kill spirochetes bacteria.
14. The method as set forth in claim 1 , wherein the oral environment of the human being is adjusted to have a pH of lower than 6.5.
15. A method of reducing the likelihood of a Porphyromonas gingivalis infection in a human being comprising,
orally administering to a human being a first composition comprising an anti-biofilm agent, said anti-biofilm agent comprising a mouthwash, an oral strip or toothpaste;
administering to the human being a second composition that is effective to one of slow down the breakdown of collagen or inhibit the production of collagenase;
orally administering to the human being a third composition in an effective amount to reduce the growth of Porphyromonas gingivalis bacteria residing on the subgingival tooth area of the human being, wherein the method reduces the likelihood of a Porphyromonas gingivalis infection in the human being and reduces the virulence factor gingipain.
16. The method as set forth in claim 15 , further comprising administering to the human being a compound that facilitates the growth of desired bacteria beneficial to a person's health, said desired bacteria comprising one of a bacterium of the genus Rothia , and a bacterium of the species Streptococcus salivarius.
17. The method as set forth in claim 15 , further comprising orally administering an antibiotic that comprises one of azithromycin, metronidazole and ceftriaxone.
18. The method as set forth in claim 15 , further comprising reducing the amount of F. nucleatum in the human being's oral cavity.
19. A method of reducing the likelihood of a Porphyromonas gingivalis infection in a human being comprising,
adjusting the oral cavity pH of the human being to have a pH of lower than 6.5;
reducing the amount of Fusobacterium nucleatum in the human being's oral cavity;
orally administering to a human being a first composition comprising an anti-biofilm agent,
orally administering to the human being a second composition that is effective to one of slow down the breakdown of collagen or inhibit the production of collagenase, said second composition including at least about 200 mg xylitol,
orally administering to the human being zinc or a non-toxic zinc salt;
orally administering to the human being a third composition in an effective amount to reduce the growth of Porphyromonas gingivalis bacteria residing on the subgingival tooth area of the human being, wherein the method reduces the likelihood of a Porphyromonas gingivalis infection in the human being and reduces the virulence factor gingipain, and
wherein said anti-biofilm agent, said second composition and said third composition comprise one of a mouthwash, an oral strip and toothpaste.
20. The method as set forth in claim 19 , further comprising administering to the human being a compound that facilitates the growth of desired bacteria beneficial to a person's health, said desired bacteria comprising a bacterium of the genus Rothia.